1 Study Coverage 1.1 Neurometabolic Disorders Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Introduction 1.2 Global Neurometabolic Disorders Outlook 2017 VS 2022 VS 2028 1.2.1 Global Neurometabolic Disorders Market Size for the Year 2017-2028 1.2.2 Global Neurometabolic Disorders Market Size for the Year 2017-2028 1.3 Neurometabolic Disorders Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.3.1 The Market Share of United States Neurometabolic Disorders in Global, 2017 VS 2022 VS 2028 1.3.2 The Growth Rate of Neurometabolic Disorders Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4 Neurometabolic Disorders Market Dynamics 1.4.1 Neurometabolic Disorders Industry Trends 1.4.2 Neurometabolic Disorders Market Drivers 1.4.3 Neurometabolic Disorders Market Challenges 1.4.4 Neurometabolic Disorders Market Restraints 1.5 Study Objectives 1.6 Years Considered 2 Neurometabolic Disorders by Type 2.1 Neurometabolic Disorders Market Segment by Type 2.1.1 Gaucher’s Disease 2.1.2 Fabry Disease 2.1.3 Pompe Disease 2.1.4 Mucopolysaccharidosis VI 2.1.5 Other 2.2 Global Neurometabolic Disorders Market Size by Type (2017, 2022 & 2028) 2.3 Global Neurometabolic Disorders Market Size by Type (2017-2028) 2.4 United States Neurometabolic Disorders Market Size by Type (2017, 2022 & 2028) 2.5 United States Neurometabolic Disorders Market Size by Type (2017-2028) 3 Neurometabolic Disorders by Application 3.1 Neurometabolic Disorders Market Segment by Application 3.1.1 Oral 3.1.2 Parenteral 3.2 Global Neurometabolic Disorders Market Size by Application (2017, 2022 & 2028) 3.3 Global Neurometabolic Disorders Market Size by Application (2017-2028) 3.4 United States Neurometabolic Disorders Market Size by Application (2017, 2022 & 2028) 3.5 United States Neurometabolic Disorders Market Size by Application (2017-2028) 4 Global Neurometabolic Disorders Competitor Landscape by Company 4.1 Global Neurometabolic Disorders Market Size by Company 4.1.1 Top Global Neurometabolic Disorders Companies Ranked by Revenue (2021) 4.1.2 Global Neurometabolic Disorders Revenue by Player (2017-2022) 4.2 Global Neurometabolic Disorders Concentration Ratio (CR) 4.2.1 Neurometabolic Disorders Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Companies of Neurometabolic Disorders in 2021 4.2.3 Global Neurometabolic Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Neurometabolic Disorders Headquarters, Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Type 4.3.1 Global Neurometabolic Disorders Headquarters and Area Served 4.3.2 Global Neurometabolic Disorders Companies Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Type 4.3.3 Date of International Companies Enter into Neurometabolic Disorders Market 4.4 Companies Mergers & Acquisitions, Expansion Plans 4.5 United States Neurometabolic Disorders Market Size by Company 4.5.1 Top Neurometabolic Disorders Players in United States, Ranked by Revenue (2021) 4.5.2 United States Neurometabolic Disorders Revenue by Players (2020, 2021 & 2022) 5 Global Neurometabolic Disorders Market Size by Region 5.1 Global Neurometabolic Disorders Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Neurometabolic Disorders Market Size by Region (2017-2028) 5.2.1 Global Neurometabolic Disorders Market Size by Region: 2017-2022 5.2.2 Global Neurometabolic Disorders Market Size by Region (2023-2028) 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Neurometabolic Disorders Market Size YoY Growth 2017-2028 6.1.2 North America Neurometabolic Disorders Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 U.S. 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Neurometabolic Disorders Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Neurometabolic Disorders Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.2.12 Philippines 6.3 Europe 6.3.1 Europe Neurometabolic Disorders Market Size YoY Growth 2017-2028 6.3.2 Europe Neurometabolic Disorders Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Neurometabolic Disorders Market Size YoY Growth 2017-2028 6.4.2 Latin America Neurometabolic Disorders Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Neurometabolic Disorders Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Neurometabolic Disorders Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 U.A.E 7 Company Profiles 7.1 Amicus Therapeutics 7.1.1 Amicus Therapeutics Company Details 7.1.2 Amicus Therapeutics Business Overview 7.1.3 Amicus Therapeutics Neurometabolic Disorders Introduction 7.1.4 Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2017-2022) 7.1.5 Amicus Therapeutics Recent Development 7.2 ISU Abxis 7.2.1 ISU Abxis Company Details 7.2.2 ISU Abxis Business Overview 7.2.3 ISU Abxis Neurometabolic Disorders Introduction 7.2.4 ISU Abxis Revenue in Neurometabolic Disorders Business (2017-2022) 7.2.5 ISU Abxis Recent Development 7.3 JCR Pharmaceuticals 7.3.1 JCR Pharmaceuticals Company Details 7.3.2 JCR Pharmaceuticals Business Overview 7.3.3 JCR Pharmaceuticals Neurometabolic Disorders Introduction 7.3.4 JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2017-2022) 7.3.5 JCR Pharmaceuticals Recent Development 7.4 Biosidus 7.4.1 Biosidus Company Details 7.4.2 Biosidus Business Overview 7.4.3 Biosidus Neurometabolic Disorders Introduction 7.4.4 Biosidus Revenue in Neurometabolic Disorders Business (2017-2022) 7.4.5 Biosidus Recent Development 7.5 Greenovation Biotech 7.5.1 Greenovation Biotech Company Details 7.5.2 Greenovation Biotech Business Overview 7.5.3 Greenovation Biotech Neurometabolic Disorders Introduction 7.5.4 Greenovation Biotech Revenue in Neurometabolic Disorders Business (2017-2022) 7.5.5 Greenovation Biotech Recent Development 7.6 UAB Proforma 7.6.1 UAB Proforma Company Details 7.6.2 UAB Proforma Business Overview 7.6.3 UAB Proforma Neurometabolic Disorders Introduction 7.6.4 UAB Proforma Revenue in Neurometabolic Disorders Business (2017-2022) 7.6.5 UAB Proforma Recent Development 7.7 Dong-A Socio Group 7.7.1 Dong-A Socio Group Company Details 7.7.2 Dong-A Socio Group Business Overview 7.7.3 Dong-A Socio Group Neurometabolic Disorders Introduction 7.7.4 Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2017-2022) 7.7.5 Dong-A Socio Group Recent Development 7.8 ExSAR Corporation 7.8.1 ExSAR Corporation Company Details 7.8.2 ExSAR Corporation Business Overview 7.8.3 ExSAR Corporation Neurometabolic Disorders Introduction 7.8.4 ExSAR Corporation Revenue in Neurometabolic Disorders Business (2017-2022) 7.8.5 ExSAR Corporation Recent Development 7.9 Lixte Biotechnology 7.9.1 Lixte Biotechnology Company Details 7.9.2 Lixte Biotechnology Business Overview 7.9.3 Lixte Biotechnology Neurometabolic Disorders Introduction 7.9.4 Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2017-2022) 7.9.5 Lixte Biotechnology Recent Development 7.10 Neuraltus Pharmaceuticals 7.10.1 Neuraltus Pharmaceuticals Company Details 7.10.2 Neuraltus Pharmaceuticals Business Overview 7.10.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Introduction 7.10.4 Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2017-2022) 7.10.5 Neuraltus Pharmaceuticals Recent Development 7.11 Protalix 7.11.1 Protalix Company Details 7.11.2 Protalix Business Overview 7.11.3 Protalix Neurometabolic Disorders Introduction 7.11.4 Protalix Revenue in Neurometabolic Disorders Business (2017-2022) 7.11.5 Protalix Recent Development 7.12 Pharming Group 7.12.1 Pharming Group Company Details 7.12.2 Pharming Group Business Overview 7.12.3 Pharming Group Neurometabolic Disorders Introduction 7.12.4 Pharming Group Revenue in Neurometabolic Disorders Business (2017-2022) 7.12.5 Pharming Group Recent Development 7.13 Protalix BioTherapeutics 7.13.1 Protalix BioTherapeutics Company Details 7.13.2 Protalix BioTherapeutics Business Overview 7.13.3 Protalix BioTherapeutics Neurometabolic Disorders Introduction 7.13.4 Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2017-2022) 7.13.5 Protalix BioTherapeutics Recent Development 7.14 Amicus 7.14.1 Amicus Company Details 7.14.2 Amicus Business Overview 7.14.3 Amicus Neurometabolic Disorders Introduction 7.14.4 Amicus Revenue in Neurometabolic Disorders Business (2017-2022) 7.14.5 Amicus Recent Development 7.15 Biomarin 7.15.1 Biomarin Company Details 7.15.2 Biomarin Business Overview 7.15.3 Biomarin Neurometabolic Disorders Introduction 7.15.4 Biomarin Revenue in Neurometabolic Disorders Business (2017-2022) 7.15.5 Biomarin Recent Development 7.16 Genzyme 7.16.1 Genzyme Company Details 7.16.2 Genzyme Business Overview 7.16.3 Genzyme Neurometabolic Disorders Introduction 7.16.4 Genzyme Revenue in Neurometabolic Disorders Business (2017-2022) 7.16.5 Genzyme Recent Development 7.17 Shire 7.17.1 Shire Company Details 7.17.2 Shire Business Overview 7.17.3 Shire Neurometabolic Disorders Introduction 7.17.4 Shire Revenue in Neurometabolic Disorders Business (2017-2022) 7.17.5 Shire Recent Development 7.18 Greencross 7.18.1 Greencross Company Details 7.18.2 Greencross Business Overview 7.18.3 Greencross Neurometabolic Disorders Introduction 7.18.4 Greencross Revenue in Neurometabolic Disorders Business (2017-2022) 7.18.5 Greencross Recent Development 8 Research Findings and Conclusion 9 Appendix 9.1 Research Methodology 9.1.1 Methodology/Research Approach 9.1.2 Data Source 9.2 Author Details 9.3 Disclaimer

List of Tables Table 1. Neurometabolic Disorders Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028) Table 2. Neurometabolic Disorders Market Trends Table 3. Neurometabolic Disorders Market Drivers Table 4. Neurometabolic Disorders Market Challenges Table 5. Neurometabolic Disorders Market Restraints Table 6. Global Neurometabolic Disorders Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Neurometabolic Disorders Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Neurometabolic Disorders Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Neurometabolic Disorders Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Neurometabolic Disorders Companies in Global Market, Ranking by Revenue (2021) Table 11. Global Neurometabolic Disorders Revenue by Player, (US$ Million), 2017-2022 Table 12. Global Neurometabolic Disorders Revenue Share by Player, 2017-2022 Table 13. Global Neurometabolic Disorders Companies Market Concentration Ratio (CR5 and HHI) Table 14. Global Neurometabolic Disorders by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurometabolic Disorders as of 2021) Table 15. Top Players of Neurometabolic Disorders in Global Market, Headquarters and Area Served Table 16. Companies Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Type Table 17. Date of International Companies Enter into Neurometabolic Disorders Market Table 18. Companies Mergers & Acquisitions, Expansion Plans Table 19. Top Neurometabolic Disorders Players in United States Market, Ranking by Revenue (2021) Table 20. United States Neurometabolic Disorders Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 21. United States Neurometabolic Disorders Revenue Share by Players, 2020, 2021 & 2022 Table 22. Global Neurometabolic Disorders Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 23. Global Neurometabolic Disorders Market Size by Region (2017-2022) & (US$ Million) Table 24. Global Neurometabolic Disorders Market Size Forecast by Region (2023-2028) & (US$ Million) Table 25. North America Neurometabolic Disorders Sales in Value by Country (2017-2028) & (US$ Million) Table 26. Asia Pacific Neurometabolic Disorders Sales in Value by Region (2017-2028) & (US$ Million) Table 27. Europe Neurometabolic Disorders Sales in Value by Country (2017-2028) & (US$ Million) Table 28. Latin Americaa Neurometabolic Disorders Sales in Value by Country (2017-2028) & (US$ Million) Table 29. Middle East and Africa Neurometabolic Disorders Sales in Value by Country (2017-2028) & (US$ Million) Table 30. Amicus Therapeutics Company Details Table 31. Amicus Therapeutics Business Overview Table 32. Amicus Therapeutics Neurometabolic Disorders Product Table 33. Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 34. Amicus Therapeutics Recent Development Table 35. ISU Abxis Company Details Table 36. ISU Abxis Business Overview Table 37. ISU Abxis Neurometabolic Disorders Product Table 38. ISU Abxis Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 39. ISU Abxis Recent Development Table 40. JCR Pharmaceuticals Company Details Table 41. JCR Pharmaceuticals Business Overview Table 42. JCR Pharmaceuticals Neurometabolic Disorders Product Table 43. JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 44. JCR Pharmaceuticals Recent Development Table 45. Biosidus Company Details Table 46. Biosidus Business Overview Table 47. Biosidus Neurometabolic Disorders Product Table 48. Biosidus Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 49. Biosidus Recent Development Table 50. Greenovation Biotech Company Details Table 51. Greenovation Biotech Business Overview Table 52. Greenovation Biotech Neurometabolic Disorders Product Table 53. Greenovation Biotech Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 54. Greenovation Biotech Recent Development Table 55. UAB Proforma Company Details Table 56. UAB Proforma Business Overview Table 57. UAB Proforma Neurometabolic Disorders Product Table 58. UAB Proforma Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 59. UAB Proforma Recent Development Table 60. Dong-A Socio Group Company Details Table 61. Dong-A Socio Group Business Overview Table 62. Dong-A Socio Group Neurometabolic Disorders Product Table 63. Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 64. Dong-A Socio Group Recent Development Table 65. ExSAR Corporation Company Details Table 66. ExSAR Corporation Business Overview Table 67. ExSAR Corporation Neurometabolic Disorders Product Table 68. ExSAR Corporation Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 69. ExSAR Corporation Recent Development Table 70. Lixte Biotechnology Company Details Table 71. Lixte Biotechnology Business Overview Table 72. Lixte Biotechnology Neurometabolic Disorders Product Table 73. Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 74. Lixte Biotechnology Recent Development Table 75. Neuraltus Pharmaceuticals Company Details Table 76. Neuraltus Pharmaceuticals Business Overview Table 77. Neuraltus Pharmaceuticals Neurometabolic Disorders Product Table 78. Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 79. Neuraltus Pharmaceuticals Recent Development Table 80. Protalix Company Details Table 81. Protalix Business Overview Table 82. Protalix Neurometabolic Disorders Product Table 83. Protalix Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 84. Protalix Recent Development Table 85. Pharming Group Company Details Table 86. Pharming Group Business Overview Table 87. Pharming Group Neurometabolic Disorders Product Table 88. Pharming Group Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 89. Pharming Group Recent Development Table 90. Protalix BioTherapeutics Company Details Table 91. Protalix BioTherapeutics Business Overview Table 92. Protalix BioTherapeutics Neurometabolic Disorders Product Table 93. Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 94. Protalix BioTherapeutics Recent Development Table 95. Amicus Company Details Table 96. Amicus Business Overview Table 97. Amicus Neurometabolic Disorders Product Table 98. Amicus Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 99. Amicus Recent Development Table 100. Biomarin Company Details Table 101. Biomarin Business Overview Table 102. Biomarin Neurometabolic Disorders Product Table 103. Biomarin Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 104. Biomarin Recent Development Table 105. Genzyme Company Details Table 106. Genzyme Business Overview Table 107. Genzyme Neurometabolic Disorders Product Table 108. Genzyme Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 109. Genzyme Recent Development Table 110. Shire Company Details Table 111. Shire Business Overview Table 112. Shire Neurometabolic Disorders Product Table 113. Shire Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 114. Shire Recent Development Table 115. Greencross Company Details Table 116. Greencross Business Overview Table 117. Greencross Neurometabolic Disorders Product Table 118. Greencross Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million) Table 119. Greencross Recent Development Table 120. Research Programs/Design for This Report Table 121. Key Data Information from Secondary Sources Table 122. Key Data Information from Primary Sources List of Figures Figure 1. Neurometabolic Disorders Product Picture Figure 2. Global Neurometabolic Disorders Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Neurometabolic Disorders Market Size 2017-2028 (US$ Million) Figure 4. United States Neurometabolic Disorders Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 5. United States Neurometabolic Disorders Market Size 2017-2028 (US$ Million) Figure 6. United States Neurometabolic Disorders Market Share in Global 2017-2028 Figure 7. Neurometabolic Disorders Report Years Considered Figure 8. Product Picture of Gaucher’s Disease Figure 9. Product Picture of Fabry Disease Figure 10. Product Picture of Pompe Disease Figure 11. Product Picture of Mucopolysaccharidosis VI Figure 12. Product Picture of Other Figure 13. Global Neurometabolic Disorders Market Share by Type in 2022 & 2028 Figure 14. Global Neurometabolic Disorders Market Size by Type (2017-2028) & (US$ Million) Figure 15. Global Neurometabolic Disorders Market Share by Type (2017-2028) Figure 16. United States Neurometabolic Disorders Market Share by Type in 2022 & 2028 Figure 17. United States Neurometabolic Disorders Market Size by Type (2017-2028) & (US$ Million) Figure 18. United States Neurometabolic Disorders Market Share by Type (2017-2028) Figure 19. Product Picture of Oral Figure 20. Product Picture of Parenteral Figure 21. Global Neurometabolic Disorders Market Share by Application in 2022 & 2028 Figure 22. Global Neurometabolic Disorders Market Size by Application (2017-2028) & (US$ Million) Figure 23. Global Neurometabolic Disorders Market Share by Application (2017-2028) Figure 24. United States Neurometabolic Disorders Market Share by Application in 2022 & 2028 Figure 25. United States Neurometabolic Disorders Market Size by Application (2017-2028) & (US$ Million) Figure 26. United States Neurometabolic Disorders Market Share by Application (2017-2028) Figure 27. North America Neurometabolic Disorders Market Size Growth Rate 2017-2028 (US$ Million) Figure 28. U.S. Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 29. Canada Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 30. Europe Neurometabolic Disorders Market Size Growth Rate 2017-2028 (US$ Million) Figure 31. Germany Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 32. France Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 33. U.K. Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 34. Italy Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 35. Russia Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 36. Asia-Pacific Neurometabolic Disorders Market Size Growth Rate 2017-2028 (US$ Million) Figure 37. China Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 38. Japan Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 39. South Korea Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 40. India Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 41. Australia Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 42. Taiwan Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 43. Indonesia Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 44. Thailand Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 45. Malaysia Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 46. Philippines Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 47. Latin America Neurometabolic Disorders Market Size Growth Rate 2017-2028 (US$ Million) Figure 48. Mexico Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 49. Brazil Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 50. Argentina Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 51. Middle East & Africa Neurometabolic Disorders Market Size Growth Rate 2017-2028 (US$ Million) Figure 52. Turkey Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 53. Saudi Arabia Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 54. U.A.E Neurometabolic Disorders Market Size Growth Rate (2017-2028) & (US$ Million) Figure 55. Amicus Therapeutics Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 56. ISU Abxis Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 57. JCR Pharmaceuticals Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 58. Biosidus Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 59. Greenovation Biotech Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 60. UAB Proforma Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 61. Dong-A Socio Group Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 62. ExSAR Corporation Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 63. Lixte Biotechnology Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 64. Neuraltus Pharmaceuticals Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 65. Protalix Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 66. Pharming Group Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 67. Protalix BioTherapeutics Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 68. Amicus Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 69. Biomarin Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 70. Genzyme Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 71. Shire Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 72. Greencross Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022) Figure 73. Bottom-up and Top-down Approaches for This Report Figure 74. Data Triangulation Figure 75. Key Executives Interviewed

Amicus Therapeutics ISU Abxis JCR Pharmaceuticals Biosidus Greenovation Biotech UAB Proforma Dong-A Socio Group ExSAR Corporation Lixte Biotechnology Neuraltus Pharmaceuticals Protalix Pharming Group Protalix BioTherapeutics Amicus Biomarin Genzyme Shire Greencross